Corporate Information | Press & Media | For Investors

[Press Release] Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis

by

Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica.

[Press Release] ThinkGenetic Closes $1.5M Angel Round of Funding

by

ThinkGenetic, Inc., makers of an artificial intelligence-driven SymptomMatcher™​ for genetic disorders, today announced the successful close of its angel round of funding for $1.5M.

Together let’s systematically accelerate detecting at-risk  individuals.

Request a Demo

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

ThinkGenetic does not provide medical advice, diagnosis or treatment. Click here for more information.